Lykan Bioscience to grow its cell therapy manufacturing capabilities
CDMO’s expansion of Hopkinton, MA facility will include seven new ISO 7 cGMP suites
Lykan Bioscience, a contract development and manufacturing organization (CDMO) that specializes in cell-based therapies, is expanding its state-of-the-art plant in Hopkinton, MA.
The addition features seven ISO 7 current good manufacturing practice (cGMP) suites that will join the existing facility, which will have capabilities for both autologous and allogeneic production. This brings the total number of clinical and commercial cGMP manufacturing suites to 15. Further, 1,700 square feet will function as a laboratory that will expand processing and analytical development capabilities, which support the innovation of chemistry, manufacturing and controls, along with partner programs.
The CDMO notes that the expansion comes as a result of the demand for cell therapy process development and manufacturing. The seven suites’ expected completion date is Q4 of 2022, while the company's new laboratory is anticipated to be functional by Q4 of this year.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
